6-Minute Walk Test
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In addition to increased mortality, heart failure (HF) results in functional disability and lower quality-of-life. [1] [2] [3] In HF, the prevalence of depression is at least 20%. 4 The World Health
Organization World Health Survey across 60 countries found that depression comorbid with one or more chronic diseases had the worst health function scores of all the disease states, even after adjusting for socioeconomic factors. 5 Depression is an independent risk factor for worsening health status and reduced quality of life in patients with HF. [6] [7] [8] [9] [10] [11] To elucidate the temporal relationship between depression and health status in patients with HF, this study examined whether antidepressant intervention and successful depression treatment (i.e., remission from depression), affect the health status. A secondary analysis is conducted from the Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) database to examine predetermined health status outcomes that were assessed via the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Medical Outcomes Study 36-Item Short Form
Health Survey (SF-36), and the 6-minutes walk test (6MWT). We hypothesize that depression remission will result in significant improvement of health status in HF patients with comorbid major depressive disorder (MDD).
Methods

Study Description
A complete description of the SADHART-CHF trial design and primary findings has been published in detail elsewhere. [12] [13] [14] In brief, SADHART-CHF is the first and the largest randomized clinical trial examining the effects of a selective serotonin reuptake inhibitor (SSRI) on depression and cardiac outcomes in patient with HF and comorbid MDD. The protocol was reviewed and approved by the institutional review board for each center. The study recruited ducted from th th h h h h he e
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Depression Measurement and Comparison
The 17-item Hamilton Depression Rating Scale (HDRS) was completed at baseline and at 2 week intervals during the 12-week treatment phase and at the end of the 12-week intervention.
Depression remission was defined as HDRS <8 during the last depression assessment. Patients whose HDRS remained 8 were considered non-remission. Participants (n=67, 14.3%) who dropped out without having a repeat HDRS were excluded.
Patient-reported Outcomes (PRO) for Health Status
In addition to the primary outcome of depression remission, a priori outcome measurements included patient-reported health status outcomes. 12 The health status outcomes were ascertained at baseline prior to randomization and the end of 12-week intervention via the Kansas City Cardiomyopathy Questionnaire (KCCQ), total and subscale scores, the Medical KCCQ is a 23-item self-administered disease specific questionnaire, scored from 0 to 100 with higher scores corresponding to better health status. In addition to the overall summary score, we also examined score from the subscales for Social Limitation, Quality-Of-Life, Symptom The 6MWT reflects a global and integrated response of the body systems to exercise testing and closely mimics everyday activity. It examines overall functional capacity and serves as a simple prognosticator.
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Statistical Analysis
Statistical analyses were performed using SAS, version 9.1 (SAS Incorporated, Cary, NC). Descriptive statistics were reported for the depression remission and non-remission groups.
Differences of depression treatment, and remission on health status scores with categorical variables (e.g. gender, race etc) were examined using chi-squared test, while for the continuous 
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was additionally added as a covariate to examine the effects of depression remission vs.
nonremission. Since a total of 10 KCCQ and 8 SF-36 outcomes were examined, a p-value <0.001 was set as statistical significance to account for examination of multiple dependent variables. Statistical significance for 6MWT was set at p<0.05 because that was the only outcome examined in this category.
Results
Participant Characteristics
A total of 469 participants were enrolled, and 402 (85.7%) had least one HDRS evaluation during the trial intervention phase. Of them, a total of 378 (80.6%) participants completed the 6MWT at baseline and at week-12, and 285 (70.1%) completed both baseline and 12-week KCCQ and SF-36. Of the participants who completed both the KCCQ and SF-36, 73
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The baseline HDRS scores were 16.83 ± 5.33 and 19.51 ± 5.50, in the remission and nonremission groups, respectively (p < 0.001). The health status outcomes associated with depression remission were not significantly associated with measured baseline conditions including baseline HDRS score.
Discussion
Depression is considered a major determinant of health status in patients with HF. 26,27 However, few studies have examined depression treatment on health status in HF. In a placebo-controlled pilot study (n=28), Gottlieb et al. found that paroxetine was associated with higher SF-36 psychological quality-of-life but not with physical quality-of-life. 28 In contrast, the SADHART-CHF study found that sertraline treatment did not differ from placebo in terms of depression remission and health status outcomes, although depression remission was associated with significant improvement in health status.
For the self-reported KCCQ measurements, depression remission was associated with improvement in Social Limitation, Physical Limitation, and Symptom Frequency. A 5-point change in the KCCQ is considered of minimal clinical significance 17 . In this study, the KCCQ overall summary score was about 13 point higher in the depression remission group compared to depression non-remission group. The largest difference was observed on the KCCQ Quality of Life and Social Limitation subscales, where the differences were nearly 20 points between the two groups, indicating moderate to large clinical difference. The observed finding on the KCCQ was verified by the SF-36 measurements, in that depression remission was associated with improvements in General Health Perception and Physical Function subscales. On the 6MWT, patients with depression remission were able to walk 47 meters more than those patients with ciated with hi igh gh gh gh gh g g . The strength of this study includes the use of rigorous instruments (KCCQ, SF-36, and 6MWT) to measure health status in HF, which had been extensively studied to evaluate the health impact of exercise training in HF. [29] [30] [31] [32] Most of these studies used one or two of these outcome instruments and not all three.
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We were able to demonstrate that health performance on the three outcomes measures consistently improved with depression remission.
There were limitations to this study, however. First, this study was a secondary analysis where the primary outcome of SADHART-CHF was depression remission. The health status instruments were secondary outcomes. The study was further limited by the low completion rate of KCCQ and SF-36 of 60.1% (n=282), and 6MWT of 80.6% (n=378) in 469 total participants.
Therefore the conclusion of this study may not be generlizable to participants who dropout or who did not complete the health status measurements. Non-completers were older (64.29 (11.6) vs 61.45 (9.8) p= 0.02), had larger incidence of MI (40.38% vs30.88%, p=0.04) and CABG (54.5 vs 44.5% p = 0.044). Also, the outcomes were not measured beyond the first 12-week during long-term follow-up, therefore whether the improvement persisted after 12 weeks remained unknown. Finally, we did not examine interaction effects between treatments and among independent variables. The conclusions therefore were limited to the variables examined and thus subject to unmeasured confounding effects.
In conclusion, sertraline treatment did not impact health status compared to placebo but monitoring and treatment of depression in HF to achieve remission has important impact on physical function and quality-of-life that is beyond just psychological and emotional well-being.
Sources of Funding
The SADHART-CHF study was funded by the National Institute of Mental Health (NIMH) Bethesda, Maryland. Sertraline was supplied by Pfizer, Inc., New York, New York. Pfizer had no other role in any aspect of the study.
Disclosures
None.
ed, double blin in in n n n nd d e e e e e e e he he he he he he hear ar ar ar ar ar art t t t t t t fa fa fa fa fa fa fail il il il il il ilur ur ur ur ur ur ure. A R R R R Ran an an ando do do domi mi mi mi mize ze ze ze z d, controlled tra r r rai ai aini ni ning ng ng i i in n n ch ch chro ro roni ni nic c c he he hear ar art t t fa fa fail il ilur ur ure e e: : : ef ef effe fe fect ct cts s s on on on f f fun un unct ct ctio io iona na nal l l ca ca capa pa paci ci city ty ty a a a e es s C C Ci i irc rcul ul ul lat t at tio io io i i n n 1 1 1 199 99 99 9 9 9; 9; 9; 9 9 9 9 99: 9: 9: 9 9 11 11 11 11 1 73 73 73 7 73-1 -1 -1 1 118 18 18 1 1 2 2 2 2 9) 9) 9) 9) 9) 9) 9) 2 2 2 2 2 2 
a a SG S S S S , Cuffe MS MS MS MS MS, Callwood DD R R RM, M M M M Rivel el el e elli li li li l S SK, K, K, K, K, K K K K Kri ri ri ri rish sh sh sh shna na na na nan n n R; R; R R R SA ADH DH H H HAR AR AR AR ART-T-T-T-T CH CH CH H HF F F F F In In In In Inve ve ve ve vest s s s s ig ig ig ig
